| Year |
Citation |
Score |
| 2024 |
Rakhmilevich AL, Tsarovsky NW, Felder M, Zaborek J, Moram S, Erbe AK, Pieper AA, Spiegelman DV, Cheng EM, Witt CM, Overwijk WW, Morris ZS, Sondel PM. A combined radio-immunotherapy regimen eradicates late-stage tumors in mice. Frontiers in Immunology. 15: 1419773. PMID 39076988 DOI: 10.3389/fimmu.2024.1419773 |
0.333 |
|
| 2023 |
Chen R, Coleborn E, Bhavsar C, Wang Y, Alim L, Wilkinson AN, Tran MA, Irgam G, Atluri S, Wong K, Shim JJ, Adityan S, Lee JS, Overwijk WW, Steptoe R, et al. miR-146a inhibits ovarian tumor growth via targeting immunosuppressive neutrophils and enhancing CD8 T cell infiltration. Molecular Therapy Oncolytics. 31: 100725. PMID 37781339 DOI: 10.1016/j.omto.2023.09.001 |
0.328 |
|
| 2022 |
Hirayama AV, Chou CK, Miyazaki T, Steinmetz RN, Di HA, Fraessle SP, Gauthier J, Fiorenza S, Hawkins RM, Overwijk WW, Riddell SR, Marcondes AMQ, Turtle CJ. A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR-T cell immunotherapy. Blood Advances. PMID 36332004 DOI: 10.1182/bloodadvances.2022008697 |
0.357 |
|
| 2022 |
Alonso Fernández R, Encinas J, Pierre-Louis L, Yao Y, Xu Y, Mu S, Martínez-López J, Primo D, Miyazaki T, Prabhala RH, Anderson KC, Overwijk WW, Munshi NC, Fulciniti M. Improving NK Cell Function in Multiple Myeloma with NKTR-255, a Novel Polymer-Conjugated Human IL-15. Blood Advances. PMID 35882498 DOI: 10.1182/bloodadvances.2022007985 |
0.352 |
|
| 2022 |
Singh S, Roszik J, Saini N, Singh VK, Bavisi K, Wang Z, Vien LT, Yang Z, Kundu S, Davis RE, Bover L, Diab A, Neelapu SS, Overwijk WW, Rai K, et al. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Frontiers in Immunology. 13: 794684. PMID 35720386 DOI: 10.3389/fimmu.2022.794684 |
0.431 |
|
| 2022 |
Hickman A, Koetsier J, Kurtanich T, Nielsen MC, Winn G, Wang Y, Bentebibel SE, Shi L, Punt S, Williams L, Haymaker C, Chesson CB, Fa'ak F, Dominguez A, Jones R, ... ... Overwijk WW, et al. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. The Journal of Clinical Investigation. PMID 35552271 DOI: 10.1172/JCI154152 |
0.504 |
|
| 2021 |
Pieper AA, Rakhmilevich AL, Spiegelman DV, Patel RB, Birstler J, Jin WJ, Carlson PM, Charych DH, Hank JA, Erbe AK, Overwijk WW, Morris ZS, Sondel PM. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. Journal For Immunotherapy of Cancer. 9. PMID 34172518 DOI: 10.1136/jitc-2021-002715 |
0.385 |
|
| 2021 |
Singh S, Xiao Z, Bavisi K, Roszik J, Melendez BD, Wang Z, Cantwell MJ, Davis RE, Lizee G, Hwu P, Neelapu SS, Overwijk WW, Singh M. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. Journal of Immunology (Baltimore, Md. : 1950). PMID 33722878 DOI: 10.4049/jimmunol.2000523 |
0.318 |
|
| 2020 |
Hennessy M, Wahba A, Felix K, Cabrera M, Segura MG, Kundra V, Ravoori MK, Stewart J, Kleinerman ES, Jensen VB, Gopalakrishnan V, Pena R, Quach P, Kim G, Kivimäe S, ... ... Overwijk WW, et al. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. International Journal of Cancer. PMID 33152115 DOI: 10.1002/ijc.33382 |
0.398 |
|
| 2020 |
Punt S, Malu S, McKenzie JA, Manrique SZ, Doorduijn EM, Mbofung RM, Williams L, Silverman DA, Ashkin EL, Dominguez AL, Wang Z, Chen JQ, Maiti SN, Tieu TN, Liu C, ... ... Overwijk WW, et al. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy : Cii. PMID 33123754 DOI: 10.1007/s00262-020-02748-9 |
0.389 |
|
| 2020 |
Sharma M, Khong H, Fa'ak F, Bentebibel SE, Janssen LME, Chesson BC, Creasy CA, Forget MA, Kahn LMS, Pazdrak B, Karki B, Hailemichael Y, Singh M, Vianden C, Vennam S, ... ... Overwijk WW, et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nature Communications. 11: 661. PMID 32005826 DOI: 10.1038/S41467-020-14471-1 |
0.493 |
|
| 2019 |
Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe SD, ... Overwijk WW, et al. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30647079 DOI: 10.1158/1078-0432.Ccr-18-1527 |
0.509 |
|
| 2019 |
Hurwitz ME, Cho DC, Balar AV, Curti BD, Siefker-Radtke AO, Sznol M, Kluger HM, Bernatchez C, Fanton C, Iacucci E, Liu Y, Nguyen T, Overwijk W, Zalevsky J, Tagliaferri MA, et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Journal of Clinical Oncology. 37: 2623-2623. DOI: 10.1200/Jco.2019.37.15_Suppl.2623 |
0.442 |
|
| 2019 |
Singh S, Bavisi K, Roszik J, Diab A, Davis RE, Hwu P, Overwijk WW, Singh M. Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment Cancer Research. 79: 941-941. DOI: 10.1158/1538-7445.Am2019-941 |
0.546 |
|
| 2019 |
Hailemichael Y, Vanderslice P, Market RV, Biediger RJ, Woodside DG, Marathi UK, Overwijk WW. Abstract 5010: Potentiating immune checkpoint blockade therapeutic efficacy using a small molecule activator of integrin cell adhesion receptors Cancer Research. 79: 5010-5010. DOI: 10.1158/1538-7445.Am2019-5010 |
0.527 |
|
| 2019 |
Hennessy M, Felix S, Wahba A, Kivimae S, Miyama T, Cabrera M, Segura MG, Zalevsky J, Overwijk W, Gordon N. Abstract 3210: A potential immunotherapeutic approach for the treatment of osteosarcoma Cancer Research. 79: 3210-3210. DOI: 10.1158/1538-7445.Am2019-3210 |
0.458 |
|
| 2018 |
Zhao J, Xiao Z, Li T, Chen H, Yuan Y, Wang AY, Hsiao CH, Chow DS, Overwijk WW, Li C. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. Acs Nano. PMID 30231203 DOI: 10.1021/Acsnano.8B02481 |
0.554 |
|
| 2018 |
Hailemichael Y, Singh M, Overwijk W. Vaccinating with Stem Cells to Stop Cancer. Trends in Molecular Medicine. PMID 29731352 DOI: 10.1016/J.Molmed.2018.04.006 |
0.43 |
|
| 2018 |
Khong H, Volmari A, Sharma M, Dai Z, Imo CS, Hailemichael Y, Singh M, Moore DT, Xiao Z, Huang XF, Horvath TD, Hawke DH, Overwijk WW. Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8 T Cell Response. Journal of Immunology (Baltimore, Md. : 1950). PMID 29643190 DOI: 10.4049/Jimmunol.1700467 |
0.525 |
|
| 2018 |
Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, ... ... Overwijk WW, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. The Journal of Clinical Investigation. PMID 29480817 DOI: 10.1172/Jci93303 |
0.494 |
|
| 2018 |
Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 159: 215-228. PMID 29331808 DOI: 10.1016/J.Biomaterials.2018.01.014 |
0.448 |
|
| 2018 |
Johnson DH, Bentebibel SE, Lecagoonporn S, Bernatchez C, Haymaker CL, Murthy R, Tam A, Yee C, Amaria RN, Patel SP, Tawbi HA, Glitza IC, Davies MA, Hwu W, Hwu P, ... Overwijk WW, et al. Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma. Journal of Clinical Oncology. 36: TPS3133-TPS3133. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps3133 |
0.352 |
|
| 2018 |
Scutti JAB, Vence LM, Royal RE, Wray TC, Cormier JN, Lee JE, Lucci A, Gershenwald JE, Ross MI, Wargo J, Millerchip KA, Amaria RN, Davis MA, Diab A, Glitza IC, ... ... Overwijk WW, et al. Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application Cancer Research. 78: 614-614. DOI: 10.1158/1538-7445.Am2018-614 |
0.511 |
|
| 2018 |
Zhao J, Xiao Z, Overwijk W, Li C. Abstract 1014: Pharmacological modulation of PDAC stroma to enhance checkpoint blockade immunotherapy Cancer Research. 78: 1014-1014. DOI: 10.1158/1538-7445.Am2018-1014 |
0.42 |
|
| 2017 |
Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK. Immune cell profiling in cancer: molecular approaches to cell-specific identification. Npj Precision Oncology. 1: 26. PMID 29872708 DOI: 10.1038/s41698-017-0031-0 |
0.399 |
|
| 2017 |
Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, ... ... Overwijk WW, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 8: 96496-96505. PMID 29228548 DOI: 10.18632/Oncotarget.20410 |
0.369 |
|
| 2017 |
Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, et al. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. Journal of Translational Medicine. 15: 236. PMID 29145885 DOI: 10.1186/S12967-017-1341-2 |
0.425 |
|
| 2017 |
Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, ... ... Overwijk WW, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nature Communications. 8: 1447. PMID 29129918 DOI: 10.1038/S41467-017-01572-7 |
0.493 |
|
| 2017 |
Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW. The immune system in cancer metastasis: friend or foe? Journal For Immunotherapy of Cancer. 5: 79. PMID 29037250 DOI: 10.1186/S40425-017-0283-9 |
0.495 |
|
| 2017 |
Overwijk WW. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Current Opinion in Immunology. 47: 103-109. PMID 28806603 DOI: 10.1016/J.Coi.2017.07.015 |
0.515 |
|
| 2017 |
Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, et al. Absence of Grail promotes CD8(+) T cell anti-tumour activity. Nature Communications. 8: 239. PMID 28798332 DOI: 10.1038/S41467-017-00252-W |
0.443 |
|
| 2017 |
Ritthipichai K, Haymaker C, Martinez-Paniagua M, Aschenbrenner A, Yi X, Zhang M, Kale C, Hailemichael Y, Overwijk WW, Vence L, Roszik J, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, et al. Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28754817 DOI: 10.1158/1078-0432.Ccr-16-1217 |
0.546 |
|
| 2017 |
Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, ... Overwijk WW, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Research. PMID 28685773 DOI: 10.1038/Cr.2017.90 |
0.495 |
|
| 2017 |
Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology. PMID 28371827 DOI: 10.1093/Neuonc/Nox026 |
0.354 |
|
| 2017 |
Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (New York, N.Y.). 19: 237-249. PMID 28254151 DOI: 10.1016/J.Neo.2016.07.009 |
0.487 |
|
| 2017 |
Overwijk WW. The making of a killer (T cell). Oncotarget. 10767-10768. PMID 28199955 DOI: 10.18632/Oncotarget.15229 |
0.388 |
|
| 2017 |
Uemura MI, Haymaker CL, Murthy R, James M, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo JA, Amaria RN, Patel SP, Tawbi HA, Glitza IC, Woodman SE, Hwu W, ... ... Overwijk WW, et al. Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM). Journal of Clinical Oncology. 35: 136-136. DOI: 10.1200/Jco.2017.35.7_Suppl.136 |
0.436 |
|
| 2017 |
Royal RE, Vence LM, Wray T, Cormier JN, Lee JE, Gershenwald JE, Ross MI, Wargo JA, Amaria RN, Davies MA, Diab A, Glitza IC, Hwu W, Patel SP, Woodman SE, ... Overwijk WW, et al. A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. Journal of Clinical Oncology. 35: 9582-9582. DOI: 10.1200/Jco.2017.35.15_Suppl.9582 |
0.462 |
|
| 2017 |
Hirsh V, Pignata S, Bersanelli M, Gnetti L, Azzoni C, Bottarelli L, Gasparro D, Leonardi F, Silini EM, Buti S, Wennerberg E, Mediero A, Cronstein B, Formenti S, Demaria S, ... ... Overwijk WW, et al. Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts Journal of Translational Medicine. 15. DOI: 10.1186/S12967-016-1095-2 |
0.478 |
|
| 2016 |
Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, Mehta N, Kelly RL, Szeto GL, Overwijk WW, Irvine DJ, Wittrup KD. Temporally Programmed CD8α(+) DC Activation Enhances Combination Cancer Immunotherapy. Cell Reports. 17: 2503-2511. PMID 27926855 DOI: 10.1016/J.Celrep.2016.11.020 |
0.529 |
|
| 2016 |
Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zhang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, ... Overwijk WW, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Research. PMID 27821490 DOI: 10.1158/0008-5472.Can-15-3142 |
0.458 |
|
| 2016 |
Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola FM, Hwu P, Grimm EA, Radvanyi LG. IL-2 variant circumvents ICOS+ regulatory T cell expansion and promotes NK cell activation. Cancer Immunology Research. PMID 27697858 DOI: 10.1158/2326-6066.Cir-15-0195 |
0.407 |
|
| 2016 |
Ma Q, Zhou D, DeLyria ES, Wen X, Lu W, Thapa P, Liu C, Li D, Bassett RL, Overwijk WW, Hwu P, Li C. Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 27681378 DOI: 10.1097/Cji.0000000000000145 |
0.425 |
|
| 2016 |
Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. Journal For Immunotherapy of Cancer. 4: 56. PMID 27660710 DOI: 10.1186/s40425-016-0160-y |
0.411 |
|
| 2016 |
Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, ... ... Overwijk WW, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. PMID 27301722 DOI: 10.1158/2159-8290.Cd-15-1545 |
0.481 |
|
| 2016 |
Hailemichael Y, Fu T, Woods A, Schluns K, Engelhard VH, Sharma P, Overwijk WW. Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer. Journal of Clinical Oncology. 34: 3094-3094. DOI: 10.1200/Jco.2016.34.15_Suppl.3094 |
0.473 |
|
| 2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Overwijk WW, ... ... Overwijk WW, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.464 |
|
| 2016 |
Singh M, Vianden C, Diab A, Hwu P, Overwijk WW. Abstract B022: Intratumoral CD40 activation and checkpoint blockade induces systemic anti-melanoma immunity that eradicates disseminated tumors Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B022 |
0.544 |
|
| 2016 |
Hailemichael Y, Fu T, Woods A, Roszik J, Schluns KS, Engelhard VH, Sharma P, Overwijk WW. Abstract A031: Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A031 |
0.515 |
|
| 2016 |
Singh M, Vianden C, Diab A, Hwu P, Overwijk WW. Abstract LB-096: Induction of systemic immunity through single-site intratumoral CD40 activation and checkpoint blockade eradicates melanoma in the brain Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-096 |
0.464 |
|
| 2016 |
Cortez MA, Wang X, Ivan C, Schoenhals JE, Niknam S, Li A, Valdecanas D, Allison JP, Sharma P, Overwijk WW, Gomez D, Chang JY, Hahn S, Calin GA, Welsh JW. Abstract 569: MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer Cancer Research. 76: 569-569. DOI: 10.1158/1538-7445.Am2016-569 |
0.418 |
|
| 2016 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, ... ... Overwijk W, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363 |
0.558 |
|
| 2015 |
Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, et al. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology. PMID 26658052 DOI: 10.1093/Neuonc/Nov292 |
0.437 |
|
| 2015 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Overwijk WW, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283 |
0.541 |
|
| 2015 |
Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, ... ... Overwijk WW, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology. 4: e998538. PMID 26137416 DOI: 10.1080/2162402X.2014.998538 |
0.621 |
|
| 2015 |
Singh M, Overwijk WW. Intratumoral immunotherapy for melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 26050024 DOI: 10.1007/s00262-015-1727-z |
0.489 |
|
| 2015 |
Anthony SM, Howard ME, Hailemichael Y, Overwijk WW, Schluns KS. Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. Plos One. 10: e0120274. PMID 25756182 DOI: 10.1371/Journal.Pone.0120274 |
0.372 |
|
| 2015 |
Ya Z, Hailemichael Y, Overwijk W, Restifo NP. Mouse model for pre-clinical study of human cancer immunotherapy. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. 108: 20.1.1-43. PMID 25640991 DOI: 10.1002/0471142735.Im2001S108 |
0.651 |
|
| 2015 |
Overwijk WW. Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells. Nature Medicine. 21: 12-4. PMID 25569544 DOI: 10.1038/Nm.3783 |
0.504 |
|
| 2015 |
Page DB, Bourla AB, Daniyan A, Naidoo J, Smith E, Smith M, Friedman C, Khalil DN, Funt S, Shoushtari AN, Overwijk WW, Sharma P, Callahan MK. Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/S40425-015-0072-2 |
0.522 |
|
| 2015 |
Khong H, Sharma M, Dai Z, Singh M, Hailemichael Y, Overwijk W. L-tyrosine is a promising cancer vaccine adjuvant Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P440 |
0.53 |
|
| 2015 |
Singh M, Dai Z, Khong H, Vianden C, Cantwell M, Overwijk W. Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P313 |
0.448 |
|
| 2014 |
Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. International Reviews of Immunology. PMID 25259408 DOI: 10.3109/08830185.2014.956360 |
0.326 |
|
| 2014 |
Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. Journal of Immunology (Baltimore, Md. : 1950). 193: 4722-31. PMID 25252955 DOI: 10.4049/Jimmunol.1401160 |
0.494 |
|
| 2014 |
Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7: 484-92. PMID 24969538 DOI: 10.1016/J.Tranon.2014.05.008 |
0.455 |
|
| 2014 |
Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine. 20: 676-81. PMID 24859530 DOI: 10.1038/Nm.3560 |
0.505 |
|
| 2014 |
Hailemichael Y, Overwijk WW. Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. The International Journal of Biochemistry & Cell Biology. 53: 46-50. PMID 24796845 DOI: 10.1016/J.Biocel.2014.04.019 |
0.581 |
|
| 2014 |
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, ... ... Overwijk WW, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications. 5: 3459. PMID 24619206 DOI: 10.1038/Ncomms4459 |
0.305 |
|
| 2014 |
Vence LM, Kim DW, Bassett RL, Cain S, Trinh V, Patel SP, Papadopoulos NE, Bedikian AY, Kim K, Hwu P, Overwijk W, Hwu W. Correlation of immune response with clinical outcomes in melanoma patients receiving adjuvant therapy of pegylated interferon alpha-2b combined with gp100 peptide vaccine. Journal of Clinical Oncology. 32: 3026-3026. DOI: 10.1200/Jco.2014.32.15_Suppl.3026 |
0.462 |
|
| 2014 |
Singh M, Khong H, Dai Z, Vasilakos JP, Hwu P, Overwijk WW. Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P176 |
0.416 |
|
| 2014 |
Hailemichael Y, Fu T, Khong H, Dai Z, Sharma P, Overwijk WW. Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P14 |
0.371 |
|
| 2014 |
Dalton HJ, Pradeep S, Armaiz-Pena GN, Previs R, Davis A, Rupaimoole R, Zand B, Hailemichael Y, Overwijk WW, Lopez-Berestein G, Sood AK. Abstract 2982: Macrophages modulate adaptive resistance to anti-angiogenic therapy Cancer Research. 74: 2982-2982. DOI: 10.1158/1538-7445.Am2014-2982 |
0.408 |
|
| 2014 |
Nduom EK, Wei J, Kong L, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Chen JQ, Ji Y, Radvanyi L, Fuller GN, Gilbert M, ... ... Overwijk W, et al. IT-22 * TARGETING THE IMMUNE CHECKPOINT NETWORK WITH miR-138 EXERTS THERAPEUTIC EFFICACY IN MURINE MODELS OF GLIOMA Neuro-Oncology. 16: v114-v114. DOI: 10.1093/Neuonc/Nou258.20 |
0.39 |
|
| 2013 |
Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. Journal For Immunotherapy of Cancer. 1: 11. PMID 24829748 DOI: 10.1186/2051-1426-1-11 |
0.584 |
|
| 2013 |
Hailemichael Y, Overwijk WW. Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology. 2: e24743. PMID 24073366 DOI: 10.4161/Onci.24743 |
0.517 |
|
| 2013 |
Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, et al. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 276-86. PMID 23603862 DOI: 10.1097/Cji.0B013E31829419F3 |
0.477 |
|
| 2013 |
Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, ... ... Overwijk WW, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion Nature Medicine. 19: 465-472. PMID 23455713 DOI: 10.1038/Nm.3105 |
0.545 |
|
| 2013 |
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1225-31. PMID 23307859 DOI: 10.1158/1078-0432.Ccr-12-1630 |
0.438 |
|
| 2013 |
Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, ... ... Overwijk WW, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 393-403. PMID 23204132 DOI: 10.1158/1078-0432.Ccr-12-1626 |
0.478 |
|
| 2013 |
Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW, Hwu P, Prieto VG. Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype. The American Journal of Dermatopathology. 35: 184-90. PMID 23147350 DOI: 10.1097/Dad.0B013E31825B2506 |
0.339 |
|
| 2013 |
Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annual Review of Medicine. 64: 71-90. PMID 23092383 DOI: 10.1146/Annurev-Med-112311-083918 |
0.445 |
|
| 2013 |
Sim GC, Grimm E, Dai Z, Overwijk W, Hwu P, Radvanyi L. IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P89 |
0.37 |
|
| 2013 |
Mbofung R, Peng W, Liu C, Xu C, Malu S, Yang Y, Ma W, Wang Z, Overwijk W, Davis E, Lee B, Hwu P. The role of transcription factor Runx2 in tumor infiltrating T cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P23 |
0.544 |
|
| 2012 |
Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 120: 4533-43. PMID 22936666 DOI: 10.1182/Blood-2012-02-407163 |
0.576 |
|
| 2012 |
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Research. 72: 5209-18. PMID 22915761 DOI: 10.1158/0008-5472.Can-12-1187 |
0.51 |
|
| 2012 |
Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. Journal of Immunology (Baltimore, Md. : 1950). 188: 5365-76. PMID 22529296 DOI: 10.4049/Jimmunol.1103553 |
0.474 |
|
| 2012 |
Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 276-82. PMID 22421945 DOI: 10.1097/Cji.0B013E31824E7F43 |
0.488 |
|
| 2012 |
Sikora AG, Hailemichael Y, Overwijk WW. Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy. 4: 141-3. PMID 22339456 DOI: 10.2217/Imt.11.177 |
0.369 |
|
| 2012 |
Huang X, Gelbard A, Li HS, Rodríguez-Cruz TG, Lou Y, Liu C, Hailemichael Y, Nanda VGY, Davies MA, Liu Y, Watowich SS, Overwijk WW. Abstract 5396: Interferon-α receptor dependent and independent inhibition of type I interferon production in plasmacytoid dendritic cells from mice and melanoma patients Cancer Research. 72: 5396-5396. DOI: 10.1158/1538-7445.Am2012-5396 |
0.346 |
|
| 2012 |
Peng W, Liu C, Xu C, Chen J, Lou Y, Overwijk W, Lizée G, Yagita H, Hwu P. Abstract 4385: PD-1 blockade enhances T-cell migration to tumor through induction of IFN-γ inducible chemokines Cancer Research. 72: 4385-4385. DOI: 10.1158/1538-7445.Am2012-4385 |
0.527 |
|
| 2012 |
Singh M, Liu C, Lou Y, Gregorio J, Conrad C, Hwu P, Overwijk WW, Gilliet M. Abstract 1580: LL-37-mediates tumor antigen-specific-T cell expansion and tumor regression Immunology. 72: 1580-1580. DOI: 10.1158/1538-7445.Am2012-1580 |
0.532 |
|
| 2011 |
Rodríguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, Lizée G. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. Plos One. 6: e22939. PMID 21860662 DOI: 10.1371/Journal.Pone.0022939 |
0.528 |
|
| 2011 |
Li HS, Gelbard A, Martinez GJ, Esashi E, Zhang H, Nguyen-Jackson H, Liu YJ, Overwijk WW, Watowich SS. Cell-intrinsic role for IFN-α-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. Blood. 118: 3879-89. PMID 21828128 DOI: 10.1182/Blood-2011-04-349761 |
0.352 |
|
| 2011 |
Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4882-91. PMID 21632855 DOI: 10.1158/1078-0432.Ccr-10-2769 |
0.476 |
|
| 2011 |
Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P. Antitumor activity mediated by CpG: the route of administration is critical. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 279-88. PMID 21389870 DOI: 10.1097/Cji.0B013E31820D2A05 |
0.56 |
|
| 2011 |
Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW. Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines Vaccine. 29: 3476-3482. PMID 21382485 DOI: 10.1016/J.Vaccine.2011.02.061 |
0.534 |
|
| 2010 |
Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5458-68. PMID 20889916 DOI: 10.1158/1078-0432.Ccr-10-0712 |
0.536 |
|
| 2010 |
Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2550-61. PMID 20388845 DOI: 10.1158/1078-0432.Ccr-10-0279 |
0.377 |
|
| 2010 |
Frasca L, Stonier SW, Overwijk WW, Schluns KS. Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types. Journal of Leukocyte Biology. 88: 69-78. PMID 20354106 DOI: 10.1189/Jlb.1209816 |
0.419 |
|
| 2010 |
Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1834-44. PMID 20215556 DOI: 10.1158/1078-0432.Ccr-09-3123 |
0.315 |
|
| 2009 |
Peddareddigari VR, Miller PW, Nebiyou BB, Overwijk WW, Ross MI, Lee JE, Gershenwald JE, Prieto VG, Hwu P, Radvanyi L. Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3021. PMID 27962071 DOI: 10.1200/Jco.2009.27.15_Suppl.3021 |
0.397 |
|
| 2009 |
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31: 787-98. PMID 19879162 DOI: 10.1016/J.Immuni.2009.09.014 |
0.672 |
|
| 2009 |
Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, Frasca L, Lou Y, Liu C, Andersson HA, Hwu P, Overwijk WW. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. Journal of Immunology (Baltimore, Md. : 1950). 182: 7398-407. PMID 19494262 DOI: 10.4049/Jimmunol.0802982 |
0.473 |
|
| 2009 |
Overwijk WW, Schluns KS. Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clinical Immunology (Orlando, Fla.). 132: 153-65. PMID 19428306 DOI: 10.1016/J.Clim.2009.03.512 |
0.404 |
|
| 2009 |
Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 27: 3484-8. PMID 19200815 DOI: 10.1016/J.Vaccine.2009.01.047 |
0.435 |
|
| 2008 |
Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proceedings of the National Academy of Sciences of the United States of America. 105: 14342-6. PMID 18794521 DOI: 10.1073/Pnas.0804105105 |
0.538 |
|
| 2008 |
Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. The Journal of Clinical Investigation. 118: 1165-75. PMID 18259609 DOI: 10.1172/Jci33583 |
0.559 |
|
| 2008 |
Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-cell receptor gene therapy of established tumors in a murine melanoma model. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 1-6. PMID 18157006 DOI: 10.1097/Cji.0B013E31815C193F |
0.661 |
|
| 2007 |
Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 25: 7955-61. PMID 17933439 DOI: 10.1016/J.Vaccine.2007.08.050 |
0.444 |
|
| 2007 |
Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G, Hwu P. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. International Immunology. 19: 1213-21. PMID 17898044 DOI: 10.1093/Intimm/Dxm093 |
0.402 |
|
| 2006 |
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4794-803. PMID 16914564 DOI: 10.1158/1078-0432.Ccr-06-0944 |
0.581 |
|
| 2006 |
Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. Journal of Immunology (Baltimore, Md. : 1950). 176: 5213-22. PMID 16621986 DOI: 10.4049/Jimmunol.176.9.5213 |
0.608 |
|
| 2006 |
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2359s-2365s. PMID 16609059 DOI: 10.1158/1078-0432.Ccr-05-2537 |
0.574 |
|
| 2005 |
Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Current Opinion in Immunology. 17: 187-94. PMID 15766680 DOI: 10.1016/J.Coi.2005.01.011 |
0.584 |
|
| 2005 |
Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 2591-601. PMID 15728465 DOI: 10.4049/Jimmunol.174.5.2591 |
0.625 |
|
| 2003 |
Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. The Journal of Experimental Medicine. 198: 569-80. PMID 12925674 DOI: 10.1084/Jem.20030590 |
0.696 |
|
| 2002 |
Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. The Prostate. 53: 183-91. PMID 12386918 DOI: 10.1002/Pros.10136 |
0.635 |
|
| 2001 |
Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 20.1. PMID 18432774 DOI: 10.1002/0471142735.Im2001S39 |
0.595 |
|
| 2001 |
Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P. Immunization against endogenous retroviral tumor-associated antigens. Cancer Research. 61: 7920-4. PMID 11691813 |
0.635 |
|
| 2001 |
van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. The Journal of Experimental Medicine. 194: 481-9. PMID 11514604 DOI: 10.1084/Jem.194.4.481 |
0.713 |
|
| 2001 |
Overwijk WW, Restifo NP. Creating therapeutic cancer vaccines: notes from the battlefield. Trends in Immunology. 22: 5-7. PMID 11286676 DOI: 10.1016/S1471-4906(00)01793-2 |
0.655 |
|
| 2000 |
Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Critical Reviews in Immunology. 20: 433-50. PMID 11396680 DOI: 10.1615/Critrevimmunol.V20.I6.10 |
0.671 |
|
| 2000 |
Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 20: 589-96. PMID 10888115 DOI: 10.1089/10799900050044787 |
0.635 |
|
| 2000 |
Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA. An autologous oral DNA vaccine protects against murine melanoma. Proceedings of the National Academy of Sciences of the United States of America. 97: 5492-7. PMID 10779556 DOI: 10.1073/Pnas.090097697 |
0.666 |
|
| 2000 |
Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. The Journal of Experimental Medicine. 191: 1221-32. PMID 10748239 DOI: 10.1084/Jem.191.7.1221 |
0.61 |
|
| 2000 |
Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. The Cancer Journal From Scientific American. 6: S76-80. PMID 10685664 |
0.595 |
|
| 2000 |
Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Research. 60: 253-8. PMID 10667570 |
0.612 |
|
| 2000 |
Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. Journal of Immunology (Baltimore, Md. : 1950). 164: 562-5. PMID 10623795 DOI: 10.4049/Jimmunol.164.2.562 |
0.654 |
|
| 1999 |
Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 96: 2982-7. PMID 10077623 DOI: 10.1073/Pnas.96.6.2982 |
0.682 |
|
| 1999 |
Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Mulé JJ, Imperiale MJ, Restifo NP, Sanda MG. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen Journal of the National Cancer Institute. 91: 169-175. PMID 9923859 DOI: 10.1093/Jnci/91.2.169 |
0.689 |
|
| 1998 |
Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. Journal of the National Cancer Institute. 90: 1881-7. PMID 9862625 DOI: 10.1093/Jnci/90.24.1881 |
0.649 |
|
| 1998 |
Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. Journal of Immunology (Baltimore, Md. : 1950). 161: 5313-20. PMID 9820504 |
0.592 |
|
| 1998 |
Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. The Journal of Experimental Medicine. 188: 277-86. PMID 9670040 DOI: 10.1084/Jem.188.2.277 |
0.668 |
|
| 1997 |
Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro Journal of Immunotherapy. 20: 276-286. PMID 9220317 DOI: 10.1097/00002371-199707000-00004 |
0.675 |
|
| 1997 |
Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods (San Diego, Calif.). 12: 117-23. PMID 9184376 DOI: 10.1006/Meth.1997.0461 |
0.598 |
|
| 1997 |
Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 15: 387-94. PMID 9141209 DOI: 10.1016/S0264-410X(96)00195-8 |
0.595 |
|
| 1997 |
Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. Journal of Immunotherapy (Hagerstown, Md. : 1997). 20: 15-25. PMID 9101410 DOI: 10.1097/00002371-199701000-00002 |
0.664 |
|
| 1997 |
Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proceedings of the National Academy of Sciences of the United States of America. 94: 3183-8. PMID 9096367 DOI: 10.1073/Pnas.94.7.3183 |
0.608 |
|
| 1997 |
Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Advances in Experimental Medicine and Biology. 397: 7-13. PMID 8718576 DOI: 10.1007/978-1-4899-1382-1_2 |
0.62 |
|
| 1997 |
Bronte V, Pericle F, Wang M, Overwijk WW, Restifo NP. Identification of a feed-back circuit regulating the immune response and operating under different conditions of immunosuppression Immunology Letters. 56: 247. DOI: 10.1016/S0165-2478(97)85983-4 |
0.485 |
|
| Show low-probability matches. |